Peptides / Sexual health and hormones

Synthetic analog · 10 amino acids · 1,269.4 Da

Goserelin

ApprovedBanned in sport

Goserelin (Zoladex) is a GnRH agonist implant approved in the US for prostate cancer, breast cancer and endometriosis, also approved in EU countries, and banned in sport. Studies in people tested it on sex hormones, tumor growth, survival and bone, and tracked side effects. PepBank shows 505 results on goserelin from 100 studies in people, and 78 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as Zoladex

10 amino acids, from first to lastEHWSYSLRPX

Evidence level: Large trials in people505 of 583 results come from studies in people, including randomized trials.

Results in people

505

87% of 583 results

Results in animals

12% of 583 results

Results in lab cells

1% of 583 results

From computer models

0% of 583 results

Overview

Goserelin at a glance

What it is	Synthetic analog, 10 amino acids
Approval	Approved in the US and EU (Zoladex)
In sport	Banned in sport (WADA S2.2.1)
Studies	119 studies with results. 116 of them gave goserelin, with 583 results. 505 in people72 in animals6 in lab cells
Best study in people	Randomized controlled trial with 743 people (2019)
Clinical trials	309 registered: 71 active or planned, 89 with posted results
Community use	Palliative treatment of advanced carcinoma of the prostate with the Zoladex goserelin acetate implant, equivalent to 3.6 mg goserelin.

The science

What is goserelin?

Goserelin is a GnRH agonist analog with D-Ser(O-tert-butyl) at position 6 and azaglycinamide at position 10.

Amino acids in one chain

The history of goserelin

1987
The oldest paper on goserelin in PepBank is from 1987.
1994October
A registered trial of goserelin started (NCT00002597).

Goserelin structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 10 amino acidsFrom the first amino acid to the last

−E1HWSY5SL+RPX10

Darker means more water-repelling+ and − show charge in the bodyOutlined: changed amino acid

Structure

Goserelin is a synthetic analog of 10 amino acids, with no ring, 3 changed amino acids.

Formula

C₅₉H₈₄N₁₈O₁₄

Molecular weight

1,269.4 g/mol

CAS number

65807-02-5

Target

Gonadotropin-releasing hormone receptor (gene GNRHR): agonistEvidence: Official prescribing information, mechanism of action

Development

Highest phase: past the trial stage (see status).

Identifiers

PubChem 5311128, ChEMBL CHEMBL1201247, UNII 0F65R8P09N, DrugBank DB00014

Full sequence, SMILES and InChIKey

Three-letter sequence
pyro-Glu-His-Trp-Ser-Tyr-D-Ser(O-tert-butyl)-Leu-Arg-Pro-Azagly-NH2

InChIKey
BLCLNMBMMGCOAS-URPVMXJPSA-N

SMILES
CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6

See charge, composition and 3D structure on the Scientific page

The evidence

What goserelin studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Large trials in people505 of 583 results come from studies in people, including randomized trials.

Sex hormones and fertility

149 results · 108 in people · 41 animal

In women receiving breast cancer chemotherapy, goserelin reduced absent periods compared with controls. Annals of oncology, 2017

Top results

In women receiving breast cancer chemotherapy, goserelin reduced absent periods compared with controls. (Annals of oncology, 2017)
In Chinese men with prostate cancer, degarelix was non-inferior to goserelin for maintaining castrate testosterone. (Asian journal of urology, 2020)
In premenopausal women with uterine fibroids, goserelin reduced womb lining thickness compared with placebos. (Fertility and sterility, 2003)

Cancer

114 results · 105 in people · 7 animal · 2 lab

In men with prostate cancer after surgery, adding goserelin increased progression-free survival compared with radiotherapy alone. The Lancet. Oncology, 2019

Top results

In men with prostate cancer after surgery, adding goserelin increased progression-free survival compared with radiotherapy alone. (The Lancet. Oncology, 2019)
In women with ER-negative breast cancer, five-year disease-free survival was lower with goserelin alone than CMF alone. (Journal of the National Cancer Institute, 2003)
In locally advanced prostate cancer, longer goserelin treatment improved disease-free survival compared with short-term treatment. (Journal of clinical oncology, 2008)

Survival and serious illness

48 results · 48 in people

In women with breast cancer, added goserelin improved overall survival compared with chemotherapy alone. The New England journal of medicine, 2015

Top results

In women with breast cancer, added goserelin improved overall survival compared with chemotherapy alone. (The New England journal of medicine, 2015)
In women with endometriosis, endometriosis scores fell by 53% with goserelin and 33% with danazol after 24 weeks. (Obstetrics and gynecology, 1993)
In men with prostate cancer, cardiovascular mortality did not significantly differ between longer-term and short-term goserelin. (European urology, 2008)

Bones and joints

34 results · 34 in people

In women with endometriosis, bone mineral density fell 5.4% with goserelin and rose 1.0% with danazol from baseline at treatment completion. Obstetrics and gynecology, 1993

Top results

In women with endometriosis, bone mineral density fell 5.4% with goserelin and rose 1.0% with danazol from baseline at treatment completion. (Obstetrics and gynecology, 1993)
In women with early breast cancer, spine bone density fell more with goserelin than CMF after 2 years. (Osteoporosis international, 2003)
In women, goserelin plus placebo reduced lower spine bone density compared with placebo plus placebo. (Obstetrics and gynecology, 1993)

Surgery and procedures

32 results · 32 in people

Goserelin produced a more satisfactory endometrial appearance than danazol. British journal of obstetrics and gynaecology, 1996

Top results

Goserelin produced a more satisfactory endometrial appearance than danazol. (British journal of obstetrics and gynaecology, 1996)
After endometrial ablation for dysfunctional uterine bleeding, subsequent surgery rates did not differ significantly between goserelin and sham pretreatment. (Fertility and sterility, 2001)
In women with uterine fibroids, hysterectomy was easier after goserelin than placebo. (British journal of obstetrics and gynaecology, 1994)

Muscles and tendons

17 results · 17 in people

In young men, type II myonuclear numbers remained unchanged with training under goserelin but increased by 12% under placebo. Acta physiologica, 2015

Top results

In young men, type II myonuclear numbers remained unchanged with training under goserelin but increased by 12% under placebo. (Acta physiologica, 2015)
In younger men undergoing resistance training, goserelin reduced gains in fat-free mass compared with placebo. (Journal of cachexia, sarcopenia and muscle, 2022)
In younger men undergoing resistance training, goserelin reduced muscle thickness gains compared with placebo. (Journal of cachexia, sarcopenia and muscle, 2022)

Goserelin has 1,014 linked papers. PepBank read up to 120 of the most-cited studies that gave it to people, up to 20 other studies, and the main trials.

All 119 goserelin studies by area Open the Scientific page

Key goserelin studies

Studies in people come first, then studies in animals and in the lab.

People
Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial
Carrie et al. 2019 · The Lancet. Oncology · 743 people · cited by 190
1 result
People
Efficacy and safety of degarelix in patients with prostate cancer: Results from a phase III study in China
Sun et al. 2020 · Asian journal of urology · 283 people · cited by 22
5 results
People
Efficacy and safety of 3-month dosing regimen of degarelix in Japanese subjects with prostate cancer: A phase III study
Ozono et al. 2018 · Cancer science · 234 people · cited by 19
5 results
People
Phase 3, open-label, randomized study comparing 3-monthly with monthly goserelin in pre-menopausal women with estrogen receptor-positive advanced breast cancer
Noguchi et al. 2016 · Breast cancer (Tokyo, Japan) · 222 people · cited by 34
3 results
People
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy
Moore et al. 2015 · The New England journal of medicine · 218 people · cited by 368
4 results

All 119 Goserelin studies

Goserelin clinical trials

ClinicalTrials.gov lists 309 trials of goserelin. 71 are active or planned, and 89 have posted results. PepBank does not show trial results.

Solid bars are dates that happened. Hatched bars are planned dates. Data from ClinicalTrials.gov.

Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC

Phase 3completed3,246 people

SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer

Phase 3completed3,040 people

Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

Phase 3completed2,028 people

All 100 Goserelin trials

Status and safety

Is goserelin approved?

FDA

United States

Approved

An approved medicine contains it.

EMA

European Union

Approved

An approved medicine contains it.

WADA

Sport

Banned

On the 2026 Prohibited List, section S2.2.1.

Yes. Approved in the US and EU (Zoladex). The FDA label for Zoladex says: “Zoladex 3.6 mg implant: locally confined Stage T2b-T4 prostate carcinoma with flutamide and radiotherapy; palliation of advanced prostate carcinoma; endometriosis; endometrial thinning before ablation for dysfunctional uterine bleeding; palliation of advanced breast cancer in pre- and perimenopausal women” Banned in sport (WADA S2.2.1).

Laws and labels change, so check the regulator for the current status.

Goserelin side effects and safety

PepBank has 122 safety results from studies of goserelin. 119 of them come from studies in people.

Safety results from studies (122)

In healthy women, goserelin increased depressive symptoms compared with placebo. (Biological psychiatry, 2015)
In women with breast cancer, safety and tolerability showed no clinically important differences between the goserelin regimens. (Breast cancer research and treatment, 2011)
In men with prostate cancer, cardiovascular mortality did not significantly differ between longer-term and short-term goserelin. (European urology, 2008)
In men with prostate cancer, deaths from other causes did not differ between extended goserelin and short-term treatment. (International journal of radiation oncology, biology, physics, 2017)
In women with early breast cancer, hormonal symptoms were worse with goserelin than CMF during treatment. (Journal of clinical oncology, 2003)
In men with locally advanced prostate cancer, cardiovascular mortality did not increase with goserelin plus radiation versus radiation alone. (Journal of clinical oncology, 2009)
In premenopausal breast cancer patients, death without recurrence occurred in 2 goserelin patients versus 2 CMF patients. (European journal of cancer, 2006)
In women with endometriosis, low-estrogen effects were more frequent with goserelin than danazol. (Obstetrics and gynecology, 1993)
In women with endometriosis, low-estrogen side effects were more common with goserelin than danazol. (Fertility and sterility, 1992)
In patients with prostate cancer, pain was common in both groups. (Urology, 1995)
In Chinese men with prostate cancer, adverse events were similar with goserelin and degarelix except for injection site reactions. (Asian journal of urology, 2020)
In women with endometriosis, adverse events did not differ significantly between goserelin and nafarelin. (Gynecological endocrinology, 2000)
The two goserelin depots had comparable safety profiles in advanced prostate cancer. (The Journal of urology, 1996)
Goserelin was better tolerated than danazol. (British journal of obstetrics and gynaecology, 1996)
The two goserelin depots had similar safety profiles in advanced prostate cancer. (Urology, 1996)
In premenopausal breast cancer patients, anxiety symptoms did not differ significantly among groups, including goserelin. (Acta oncologica, 2000)
In women with breast pain, side effects were more common with goserelin than sham injection. (American journal of obstetrics and gynecology, 2004)
In premenopausal women with metastatic breast cancer, hot flashes were more common with goserelin than ovariectomy. (Journal of clinical oncology, 1998)
In patients after endometriosis surgery, side-effects were more marked with goserelin than dienogest. (The journal of obstetrics and gynaecology research, 2016)
In women undergoing IVF, tiredness was significantly less with goserelin than buserelin. (Human reproduction, 1993)
In women with early breast cancer, spine bone density fell more with goserelin than CMF after 2 years. (Osteoporosis international, 2003)
In women with uterine fibroids, complications after surgery did not differ between goserelin and placebo. (British journal of obstetrics and gynaecology, 1994)
In prostate cancer patients, goserelin was better tolerated than diethylstilbestrol. (The Prostate, 1991)
In prostate cancer patients, first-injection pain did not significantly differ between goserelin and leuprorelin. (Prostate cancer and prostatic diseases, 2005)

See every safety result on the Scientific page

Doses studied (40 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
10·8 mg on the first day of irradiation and 3 months later	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 743	Carrie 2019
3.6 mg monthly	Human	human	subcutaneous	12 months	Randomized trial in people · n = 283	Sun 2020
3.6 mg initially, then 10.8 mg every 84 days after day 28	Human	human	subcutaneous	day 28 to day 364	Randomized trial in people · n = 234	Ozono 2018
10.8 mg every 3 months	Human	human	Not reported	Not reported	Randomized trial in people · n = 222	Noguchi 2016
10.8 mg every 3 months	Human	human	Not reported	24 weeks	Randomized trial in people · n = 170	Masuda 2011
3.6 mg every 4 weeks	Human	human	subcutaneous	Until the end of the last chemotherapy cycle	Randomized trial in people · n = 60	Gerber 2011
3.6 mg implant	Human	human	Not reported	Not reported	Randomized trial in people · n = 60	Frokjaer 2015
3.6 mg per month	Human	human	Not reported	Additional 24 months	Randomized trial in people · n = 1,520	Lawton 2017
3.6 mg every 28 days	Human	human	Not reported	2 years	Randomized trial in people · n = 1,010	de 2003
3.6 mg depot every 28 days	Human	human	Not reported	8 weeks	Randomized trial in people · n = 358	Donnez 2001
3.6 mg every 28 days	Human	human	Not reported	Not reported	Randomized trial in people · n = 350	Thorpe 1996
3.6 mg every 28 days	Human	human	subcutaneous	24 weeks	Randomized trial in people · n = 315	Rock 1993
3.6 mg monthly	Human	human	subcutaneous	24 weeks	Randomized trial in people · n = 307	Shaw 1992
3.6 mg every 28 days	Human	human	Not reported	Not reported	Randomized trial in people · n = 283	Vogelzang 1995
3.6 mg	Human	human	Not reported	Not reported	Randomized trial in people · n = 164	Soloway 1991
10.8 mg every 12 weeks	Human	human	Not reported	48 weeks	Randomized trial in people · n = 160	Debruyne 1996
3.6 mg	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 160	Garry 1996
10.8 mg every 12 weeks	Human	human	Not reported	Not reported	Randomized trial in people · n = 160	Fernandez 1996
3.6 mg/month	Human	human	Not reported	6 months	Randomized trial in people · n = 147	Mansel 2004
3.6 mg every 4 weeks	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 136	Taylor 1998
3.6 mg	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 100	Tapanainen 1993
3.6 mg every 28 days	Human	human	Not reported	2 years	Randomized trial in people · n = 96	Fogelman 2003
3.6 mg every 28 days	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 67	Citrin 1991
3.6 mg monthly	Human	human	subcutaneous implant	2 months	Randomized trial in people · n = 60	Fraser 1996
3.6 mg	Human	human	subcutaneous implant	Not reported	Randomized trial in people · n = 60	Sørensen 1997
3.6 mg/month	Human	human	Not reported	6 months	Randomized trial in people · n = 47	Soysal 2001
3.6 mg/4 weeks	Human	human	subcutaneous	6 months	Randomized trial in people · n = 33	Lemay 1991
3.6 mg monthly	Human	human	subcutaneous injection	3 months	Randomized trial in people · n = 27	West 1994
3.6 mg every 4 wk	Human	human	subcutaneous	12 wk	Randomized trial in people · n = 22	Kvorning 2006
3.6 mg every 4 weeks	Human	human	Not reported	12 weeks	Randomized trial in people · n = 22	Kvorning 2007
3.6 mg	Human	human	injection	Not reported	Randomized trial in people · n = 16	Gharahdaghi 2022
3.6 mg/28 d	Human	human	subcutaneous	Not reported	Randomized trial in people	Peeling 1989
3.6 mg every 4 weeks	Human	human	Not reported	6 months	Randomized trial in people	Leather 1993
3.6 mg every 28 days	Human	human	Not reported	48 weeks	Randomized trial in people	Zinner 2004
3.6 mg every 4 weeks	Human	human	injection	2 years	Randomized trial in people	Hackshaw 2009
3.6 mg once every 4 weeks	Human	human	subcutaneous	12 weeks	Randomized trial in people	Donnez 2003
3.6 mg four weekly	Human	human	implant	6 months	Randomized trial in people	Leather 1999
3.6 mg once every 28 days	Human	human	subcutaneous	2 years	Randomized trial in people	Johansson 2022
3.6 mg once monthly	Human	human	Not reported	12 weeks	Randomized trial in people	Benagiano 1996
10.8 mg	Human	human	Not reported	Not reported	Trial in people without random groups · n = 22	Oefelein 2003

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

The cited US label supports this selected regimen for palliative treatment of advanced prostate carcinoma. It uses the Zoladex goserelin acetate implant.

Reported routines and cautions

What people use it for

Palliative treatment of advanced carcinoma of the prostate with the Zoladex goserelin acetate implant, equivalent to 3.6 mg goserelin.S1

Reported regimens

Regimens that community sources report for Goserelin. Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
Palliative treatment of advanced carcinoma of the prostate with the Zoladex goserelin acetate implant, equivalent to 3.6 mg goserelin.Official label dosing of an approved product	subcutaneous implantAdminister into the anterior abdominal wall below the navel line with an aseptic technique under physician supervision. Do not penetrate muscle or peritoneum.	3.6 mg per dose	every 28 days	Long-term administration unless clinically inappropriate.	Single official US label source.	S1

Cautions

The label warns about tumor flare and injection-site or vascular injury. It reports hyperglycemia, diabetes and cardiovascular risks with GnRH analogs in men. Androgen deprivation therapy may prolong QT. Known hypersensitivity to GnRH, its agonist analogs or implant components is a contraindication.S1
The September 2025 label warns about severe skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Depression can occur or worsen.S3

Status notes

The EMA list dated 12 January 2017 records nationally authorised goserelin products. It does not establish central EMA authorisation or current availability in each country.S2

Community sources

S1Zoladex US prescribing information (opens in a new tab)dailymed.nlm.nih.gov
S2EMA regulatory information (opens in a new tab)ema.europa.eu
S3FDA Zoladex 3.6 mg label, revised September 2025 (opens in a new tab)accessdata.fda.gov

Gaps

This check establishes one selected label regimen. It does not establish an independent non-vendor community regimen. The cited label has other indications and administration conditions. This summary does not replace its full instructions.

Questions and more

Ask a question about goserelin

The answer links to every study it uses.

What does the evidence say about goserelin?Is goserelin tested in people?Compare with Triptorelin (Trelstar, Decapeptyl)Compare with Leuprolide

Sources

Database: PepBank data for goserelin (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Trial registry: ClinicalTrials.gov
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about goserelin

Goserelin

ApprovedBanned in sport

Also known as Zoladex

What it is

Synthetic analog, 10 amino acids

Approval

Approved in the US and EU (Zoladex)

In sport

Banned in sport (WADA S2.2.1)

Studies

119 studies with results. 116 of them gave goserelin, with 583 results.
505 in people72 in animals6 in lab cells

Best study in people

Randomized controlled trial with 743 people (2019)

Clinical trials

309 registered: 71 active or planned, 89 with posted results

Community use

Palliative treatment of advanced carcinoma of the prostate with the Zoladex goserelin acetate implant, equivalent to 3.6 mg goserelin.

Dose as reported

Class

Species

Route

Duration

Design

Source

10·8 mg on the first day of irradiation and 3 months later

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 743

Carrie 2019

3.6 mg monthly

Human

human

subcutaneous

12 months

Randomized trial in people · n = 283

Sun 2020

3.6 mg initially, then 10.8 mg every 84 days after day 28

Human

human

subcutaneous

day 28 to day 364

Randomized trial in people · n = 234

Ozono 2018

10.8 mg every 3 months

Human

human

Not reported

Randomized trial in people · n = 222

Noguchi 2016

10.8 mg every 3 months

Human

human

Not reported

24 weeks

Randomized trial in people · n = 170

Masuda 2011

3.6 mg every 4 weeks

Human

human

subcutaneous

Until the end of the last chemotherapy cycle

Randomized trial in people · n = 60

Gerber 2011

3.6 mg implant

Human

human

Not reported

Randomized trial in people · n = 60

Frokjaer 2015

3.6 mg per month

Human

human

Not reported

Additional 24 months

Randomized trial in people · n = 1,520

Lawton 2017

3.6 mg every 28 days

Human

human

Not reported

2 years

Randomized trial in people · n = 1,010

de 2003

3.6 mg depot every 28 days

Human

human

Not reported

8 weeks

Randomized trial in people · n = 358

Donnez 2001

3.6 mg every 28 days

Human

human

Not reported

Randomized trial in people · n = 350

Thorpe 1996

3.6 mg every 28 days

Human

human

subcutaneous

24 weeks

Randomized trial in people · n = 315

Rock 1993

3.6 mg monthly

Human

human

subcutaneous

24 weeks

Randomized trial in people · n = 307

Shaw 1992

3.6 mg every 28 days

Human

human

Not reported

Randomized trial in people · n = 283

Vogelzang 1995

3.6 mg

Human

human

Not reported

Randomized trial in people · n = 164

Soloway 1991

10.8 mg every 12 weeks

Human

human

Not reported

48 weeks

Randomized trial in people · n = 160

Debruyne 1996

3.6 mg

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 160

Garry 1996

10.8 mg every 12 weeks

Human

human

Not reported

Randomized trial in people · n = 160

Fernandez 1996

3.6 mg/month

Human

human

Not reported

6 months

Randomized trial in people · n = 147

Mansel 2004

3.6 mg every 4 weeks

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 136

Taylor 1998

3.6 mg

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 100

Tapanainen 1993

3.6 mg every 28 days

Human

human

Not reported

2 years

Randomized trial in people · n = 96

Fogelman 2003

3.6 mg every 28 days

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 67

Citrin 1991

3.6 mg monthly

Human

human

subcutaneous implant

2 months

Randomized trial in people · n = 60

Fraser 1996

3.6 mg

Human

human

subcutaneous implant

Not reported

Randomized trial in people · n = 60

Sørensen 1997

3.6 mg/month

Human

human

Not reported

6 months

Randomized trial in people · n = 47

Soysal 2001

3.6 mg/4 weeks

Human

human

subcutaneous

6 months

Randomized trial in people · n = 33

Lemay 1991

3.6 mg monthly

Human

human

subcutaneous injection

3 months

Randomized trial in people · n = 27

West 1994

3.6 mg every 4 wk

Human

human

subcutaneous

12 wk

Randomized trial in people · n = 22

Kvorning 2006

3.6 mg every 4 weeks

Human

human

Not reported

12 weeks

Randomized trial in people · n = 22

Kvorning 2007

3.6 mg

Human

human

injection

Not reported

Randomized trial in people · n = 16

Gharahdaghi 2022

3.6 mg/28 d

Human

human

subcutaneous

Not reported

Randomized trial in people

Peeling 1989

3.6 mg every 4 weeks

Human

human

Not reported

6 months

Randomized trial in people

Leather 1993

3.6 mg every 28 days

Human

human

Not reported

48 weeks

Randomized trial in people

Zinner 2004

3.6 mg every 4 weeks

Human

human

injection

2 years

Randomized trial in people

Hackshaw 2009

3.6 mg once every 4 weeks

Human

human

subcutaneous

12 weeks

Randomized trial in people

Donnez 2003

3.6 mg four weekly

Human

human

implant

6 months

Randomized trial in people

Leather 1999

3.6 mg once every 28 days

Human

human

subcutaneous

2 years

Randomized trial in people

Johansson 2022

3.6 mg once monthly

Human

human

Not reported

12 weeks

Randomized trial in people

Benagiano 1996

10.8 mg

Human

human

Not reported

Trial in people without random groups · n = 22

Oefelein 2003

Context

Route

Amount

How often

How long

Agreement

Sources

Palliative treatment of advanced carcinoma of the prostate with the Zoladex goserelin acetate implant, equivalent to 3.6 mg goserelin.Official label dosing of an approved product

subcutaneous implantAdminister into the anterior abdominal wall below the navel line with an aseptic technique under physician supervision. Do not penetrate muscle or peritoneum.

3.6 mg per dose

every 28 days

Long-term administration unless clinically inappropriate.

Single official US label source.

Goserelin

Goserelin at a glance

What is goserelin?

The history of goserelin

Goserelin structure and chemistry

What goserelin studies show

Sex hormones and fertility

Cancer

Survival and serious illness

Bones and joints

Surgery and procedures

Muscles and tendons

Key goserelin studies

Goserelin clinical trials

Is goserelin approved?

Goserelin side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Status notes

Community sources

Ask a question about goserelin

Related peptides

Sources

Goserelin

Goserelin at a glance

What is goserelin?

The history of goserelin

Goserelin structure and chemistry

What goserelin studies show

Sex hormones and fertility

Cancer

Survival and serious illness

Bones and joints

Surgery and procedures

Muscles and tendons

Key goserelin studies

Goserelin clinical trials

Is goserelin approved?

Goserelin side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Status notes

Community sources

Ask a question about goserelin

Related peptides

Sources